Dr Reddys Laboratories (RDY) Share-based Compensation (2009 - 2026)

Dr Reddys Laboratories has reported Share-based Compensation for 17 years, with the latest figure at $1.0 million in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 21.71% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $4.8 million, a 4.18% decrease from a year earlier, with the FY2026 full-year figure at $3.0 million, down 40.0% from the prior year.
• Share-based Compensation was $1.0 million for Q2 2026 at Dr Reddys Laboratories, down from $1.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $1.9 million in Q2 2022, with the low at $255461.9 in Q1 2023.
• Average Share-based Compensation over 5 years is $1.3 million, with a median of $1.3 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation tumbled 86.38% in 2023, then surged 357.22% in 2024.
• Over 5 years, Share-based Compensation stood at $1.4 million in 2022, then retreated by 13.61% to $1.2 million in 2023, then grew by 7.45% to $1.3 million in 2024, then retreated by 10.26% to $1.1 million in 2025, then slipped by 10.63% to $1.0 million in 2026.
• The last three Share-based Compensation figures came in at $1.0 million (Q2 2026), $1.1 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.